ALDEYRA THERAPEUTICS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
ALDEYRA THERAPEUTICS, INC. (ALDX) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$7.96 million for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-08-09.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-08-09
- ALDEYRA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-06-30 was -$4.90M, a 234.48% decline year-over-year.
- ALDEYRA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was -$3.06M, a 425.45% decline year-over-year.
- ALDEYRA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was $29.35M.
- ALDEYRA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was -$6.60M, a 135.67% decline year-over-year.
- ALDEYRA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2018 was $27.33M, a 241.32% increase from fiscal 2017.
- ALDEYRA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $8.01M.
- ALDEYRA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$2.63M, a 143.03% decline from fiscal 2015.
- ALDEYRA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $6.12M, a 16.27% increase from fiscal 2014.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 116 month |
|---|---|---|---|---|---|
| 2019-06-30 | -$4.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$7.96M 10-Q · filed 2019-08-09 | $21.39M derived: sum of 3 quarters · filed 2019-08-09 | $14.79M derived: sum of 4 quarters · filed 2019-08-09 | |
| 2019-03-31 | -$3.06M 10-Q · filed 2019-05-10 | $26.29M derived: sum of 2 quarters · filed 2019-05-10 | $19.69M derived: sum of 3 quarters · filed 2019-05-10 | $23.33M derived: sum of 4 quarters · filed 2019-08-09 | |
| 2018-12-31 | $29.35M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | $22.75M derived: sum of 2 quarters · filed 2019-03-08 | $26.39M derived: sum of 3 quarters · filed 2019-08-09 | $27.33M 10-K · filed 2019-03-08 | |
| 2018-09-30 | -$6.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | -$2.95M derived: sum of 2 quarters · filed 2019-08-09 | -$2.01M 10-Q · filed 2018-11-14 | -$15.10M derived: sum of 4 quarters · filed 2019-08-09 | |
| 2018-06-30 | $3.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $4.58M 10-Q · filed 2019-08-09 | -$8.50M derived: sum of 3 quarters · filed 2019-08-09 | $10.00M derived: sum of 4 quarters · filed 2019-08-09 | |
| 2018-03-31 | $940.20K 10-Q · filed 2019-05-10 | -$12.14M derived: sum of 2 quarters · filed 2019-05-10 | $6.35M derived: sum of 3 quarters · filed 2019-05-10 | $1.66M derived: sum of 4 quarters · filed 2019-05-10 | |
| 2017-12-31 | -$13.08M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | $5.41M derived: sum of 2 quarters · filed 2019-03-08 | $720.49K derived: sum of 3 quarters · filed 2019-03-08 | $8.01M 10-K · filed 2019-03-08 | |
| 2017-09-30 | $18.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $13.80M derived: sum of 2 quarters · filed 2018-11-14 | $21.09M 10-Q · filed 2018-11-14 | $18.54M derived: sum of 4 quarters · filed 2018-11-14 | |
| 2017-06-30 | -$4.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $2.59M 10-Q · filed 2018-08-09 | $41.23K derived: sum of 3 quarters · filed 2018-08-09 | -$3.00M derived: sum of 4 quarters · filed 2018-08-09 | |
| 2017-03-31 | $7.29M 10-Q · filed 2018-05-15 | $4.73M derived: sum of 2 quarters · filed 2018-03-29 | $1.70M derived: sum of 3 quarters · filed 2018-03-29 | $9.15M derived: sum of 4 quarters · filed 2018-03-29 | |
| 2016-12-31 | -$2.55M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29 | -$5.59M derived: sum of 2 quarters · filed 2018-03-29 | $1.87M derived: sum of 3 quarters · filed 2018-03-29 | -$2.63M 10-K · filed 2018-03-29 | |
| 2016-09-30 | -$3.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $4.42M derived: sum of 2 quarters · filed 2017-11-09 | -$80.36K 10-Q · filed 2017-11-09 | -$16.05M derived: sum of 4 quarters · filed 2017-11-09 | |
| 2016-06-30 | $7.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | $2.96M 10-Q · filed 2017-08-07 | -$13.01M derived: sum of 3 quarters · filed 2017-05-15 | -$15.96M derived: sum of 4 quarters · filed 2017-05-15 | |
| 2016-03-31 | -$4.50M 10-Q · filed 2017-05-15 | -$20.47M derived: sum of 2 quarters · filed 2017-05-15 | -$23.42M derived: sum of 3 quarters · filed 2017-05-15 | -$5.57M derived: sum of 4 quarters · filed 2017-05-15 | |
| 2015-12-31 | -$15.97M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30 | -$18.92M derived: sum of 2 quarters · filed 2017-03-30 | -$1.07M derived: sum of 3 quarters · filed 2017-03-30 | $6.12M 10-K · filed 2017-03-30 | |
| 2015-09-30 | -$2.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $14.90M derived: sum of 2 quarters · filed 2016-11-14 | $22.09M 10-Q · filed 2016-11-14 | $20.48M derived: sum of 4 quarters · filed 2016-11-14 | |
| 2015-06-30 | $17.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | $25.04M 10-Q · filed 2016-08-10 | $23.43M derived: sum of 3 quarters · filed 2016-08-10 | $22.03M derived: sum of 4 quarters · filed 2016-08-10 | |
| 2015-03-31 | $7.19M 10-Q · filed 2016-05-09 | $5.58M derived: sum of 2 quarters · filed 2016-05-09 | $4.19M derived: sum of 3 quarters · filed 2016-05-09 | $13.58M derived: sum of 4 quarters · filed 2016-05-09 | |
| 2014-12-31 | -$1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | -$3.01M derived: sum of 2 quarters · filed 2016-03-30 | $6.38M derived: sum of 3 quarters · filed 2016-03-30 | $5.26M 10-K · filed 2016-03-30 | |
| 2014-09-30 | -$1.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $8.00M derived: sum of 2 quarters · filed 2015-11-13 | $6.88M 10-Q · filed 2015-11-13 | $7.38M derived: sum of 4 quarters · filed 2015-11-13 | |
| 2014-06-30 | $9.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $8.27M 10-Q · filed 2015-08-14 | $8.77M derived: sum of 3 quarters · filed 2015-08-14 | $10.19M derived: sum of 4 quarters · filed 2015-08-14 | |
| 2014-03-31 | -$1.12M 10-Q · filed 2015-05-14 | -$618.83K derived: sum of 2 quarters · filed 2015-05-14 | $801.98K derived: sum of 3 quarters · filed 2015-05-14 | $469.57K derived: sum of 4 quarters · filed 2015-05-14 | $2.15M 10-Q · filed 2014-06-11 |
| 2013-12-31 | $497.90K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-23 | $1.92M derived: sum of 2 quarters · filed 2015-03-23 | $1.59M derived: sum of 3 quarters · filed 2015-03-23 | $2.04M 10-K · filed 2015-03-23 | |
| 2013-09-30 | $1.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $1.09M derived: sum of 2 quarters · filed 2014-11-12 | $1.54M 10-Q · filed 2014-11-12 | ||
| 2013-06-30 | -$332.41K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $120.00K 10-Q · filed 2014-08-07 | |||
| 2013-03-31 | $452.42K 10-Q · filed 2014-06-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |